Yet, given the efficacy of the nontargeted approach, it could be used to treat locally advanced breast cancers of various phenotypes (not limited to EGFR‐positive), questioning the value of the targeted system, as nontargeted probes are easier to implement in clinics.[30]. The gene discussed is EGFR; the disease is breast carcinoma.